| Case report | Sex, age | Site | Associated malignancy | Karyotype/ cytogenetics | Treatment | Prognosis |
|
Kim 1998 [6] | Male, 57 | Duodenum | De novo | NR | Daunorubicin + Cytosine Arabinoside | Remission 7 months with no leukemia | Goor et al., 2003 [7] | Male, 27 | Duodenum | NR, 30% blasts | Inv (16) | Induction (Cytarabine + Idarubicin), consolidation (high dose Cytarabine), allo BMT | Remission 2 years | Choi et al., 2007 [2] | Male, 71 | Duodenum | CML | NR | NR | NR |
Derenzini et al., 2008 [8] | Male, 40 | Stomach (fundus, body), duodenum | De novo, AML 20 days later | 45, XY | Induction (Ara-C, Etoposide, Idarubicin, 2nd induction (Ara-C, Idarubicin) after clinical relapse, allo BMT | Expired 50 days post BMT | Ghafoor et al., 2010 [9] | Male, 17 | Duodenum | AML-M1 | NR | 2 courses induction (Ara-C, Daunorubicin, Etoposide), consolidation MACE (Amsacrine, Cytosine, Etoposide), + MIDAC (Mitoxantrone, high dose Cytarabine) | In remission 25 months post treatment | Jeong et al., 2010 [10] | Male, 35 | Duodenum jejunum, left sternocleid-omastoid | AML | 46, XY | Induction (Mitoxantrone, Etoposide, Cytarabine) | Expired due sepsis after chemotherapy | Antic et al., 2010 [11] | Female, 28 | Duodenum | Primary, AML 2 months later | 46, XX | Patient refused treatment | NR |
|
|